Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JUVENAL E MARTINEZ

Allopathic & Osteopathic Physicians Family Medicine

NPI
1558459529
CMS profile
69926
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$1,279.40

50 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,279.40 50

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–50 of 50 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JUVENAL E MARTINEZ

NPI 1558459529 · CMS profile ID 69926

Allopathic & Osteopathic Physicians / Family Medicine

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–50 of 50 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558459529?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JUVENAL E MARTINEZ, NPI 1558459529, CMS profile ID 69926. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–50 of 50 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558459529?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JUVENAL E MARTINEZ, NPI 1558459529, CMS profile ID 69926. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–50 of 50 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558459529?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JUVENAL E MARTINEZ, NPI 1558459529, CMS profile ID 69926, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–50 of 50 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1558459529?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

50 matching records · $1,279.40 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 50 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 50.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $20.0012/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898727915 CMS
IDORSIA PHARMACEUTICALS US INC $19.1712/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942812543 CMS
Lilly USA, LLC $12.3611/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918135567 CMS
Biohaven Pharmaceutical Holding Company Ltd. $22.9011/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923664641 CMS
Abbott Laboratories $63.7911/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920495857 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $27.0911/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887444011 CMS
Lilly USA, LLC $14.1210/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918105053 CMS
Bayer HealthCare Pharmaceuticals Inc. $121.6010/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930057541 CMS
Bayer HealthCare Pharmaceuticals Inc. $19.5010/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930028289 CMS
Biohaven Pharmaceutical Holding Company Ltd. $23.3209/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923664639 CMS
AstraZeneca Pharmaceuticals LP $114.2409/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915869645 CMS
AstraZeneca Pharmaceuticals LP $16.8409/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914743973 CMS
Novo Nordisk Inc $124.9909/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898628097 CMS
Novartis Pharmaceuticals Corporation $16.6609/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893942157 CMS
AstraZeneca Pharmaceuticals LP $15.0409/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915515423 CMS
Biohaven Pharmaceutical Holding Company Ltd. $24.9508/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923664637 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.5608/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959504753 CMS
Lilly USA, LLC $14.0708/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918152583 CMS
Lilly USA, LLC $13.2407/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918097235 CMS
Lilly USA, LLC $17.8907/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918097233 CMS
Biohaven Pharmaceutical Holding Company Ltd. $23.6507/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923664635 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.5607/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959625521 CMS
SANOFI-AVENTIS U.S. LLC $27.3306/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938740525 CMS
PFIZER INC. $20.4506/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949178931 CMS
Lilly USA, LLC $13.7406/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918110481 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.5606/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959710971 CMS
AstraZeneca Pharmaceuticals LP $5.2105/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915517196 CMS
AstraZeneca Pharmaceuticals LP $15.5605/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915070975 CMS
Bayer HealthCare Pharmaceuticals Inc. $19.9805/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930180815 CMS
Biohaven Pharmaceutical Holding Company Ltd. $24.3505/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923664633 CMS
Janssen Pharmaceuticals, Inc $13.8804/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885966799 CMS
SANOFI-AVENTIS U.S. LLC $23.2704/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938740505 CMS
AstraZeneca Pharmaceuticals LP $14.8904/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915068117 CMS
GlaxoSmithKline, LLC. $20.0604/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944933813 CMS
PFIZER INC. $19.6004/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949110593 CMS
Lilly USA, LLC $13.2404/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918105055 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.1604/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887444009 CMS
Novo Nordisk Inc $18.4604/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898628087 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.7304/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959537979 CMS
Bayer HealthCare Pharmaceuticals Inc. $22.2903/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929942289 CMS
SANOFI-AVENTIS U.S. LLC $21.9503/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938740487 CMS
Bayer HealthCare Pharmaceuticals Inc. $19.5802/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929955963 CMS
ABBVIE INC. $20.6902/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891107343 CMS
AstraZeneca Pharmaceuticals LP $16.2002/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915671683 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $17.0202/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959618983 CMS
Biohaven Pharmaceutical Holding Company Ltd. $19.0002/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923664631 CMS
Kowa Pharmaceuticals America, Inc. $16.4701/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 900359821 CMS
SANOFI-AVENTIS U.S. LLC $20.3601/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938740463 CMS
Biohaven Pharmaceutical Holding Company Ltd. $17.6101/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923664629 CMS
Amarin Pharma Inc. $23.2201/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 913957435 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,824.81 72
PY2020 $1,108.16 66
PY2021 $1,714.64 78
PY2022 $1,279.40 50
PY2023 $1,687.36 46
PY2024 $1,313.52 50
PY2025 $665.19 30

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,400.63 16
PY2025 Principal investigator $701,734.65 46
PY2024 Principal investigator $1,015,383.57 140
PY2023 Principal investigator $1,037,707.93 416
PY2022 Principal investigator $88,070.01 24
PY2021 Principal investigator $334,298.45 64
PY2020 Principal investigator $148,277.65 26

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

140 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6,101.06 12/06/2024 Non-covered Recipient Entity
Anchor Medical Research LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121148771
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,129.90 12/06/2024 Non-covered Recipient Entity
Anchor Medical Research LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121148773
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6,101.06 12/06/2024 Non-covered Recipient Entity
Anchor Medical Research LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121148775
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6,101.06 12/06/2024 Non-covered Recipient Entity
Anchor Medical Research LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121148777
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,050.53 12/06/2024 Non-covered Recipient Entity
Anchor Medical Research LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121148779
Principal investigator 1 Alnylam Pharmaceuticals Inc. $27,557.70 12/06/2024 Non-covered Recipient Entity
Anchor Medical Research LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121148781
Principal investigator 1 Alnylam Pharmaceuticals Inc. $84,751.56 12/06/2024 Non-covered Recipient Entity
Anchor Medical Research LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121148783
Principal investigator 1 Alnylam Pharmaceuticals Inc. $66,408.15 12/06/2024 Non-covered Recipient Entity
Anchor Medical Research LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121148785
Principal investigator 1 Alnylam Pharmaceuticals Inc. $83,249.79 12/06/2024 Non-covered Recipient Entity
Anchor Medical Research LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121148787
Principal investigator 1 Alnylam Pharmaceuticals Inc. $84,342.91 12/06/2024 Non-covered Recipient Entity
Anchor Medical Research LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121148789
Principal investigator 1 Alnylam Pharmaceuticals Inc. $40,042.51 12/06/2024 Non-covered Recipient Entity
Anchor Medical Research LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121148791
Principal investigator 1 Alnylam Pharmaceuticals Inc. $42,749.66 12/06/2024 Non-covered Recipient Entity
Anchor Medical Research LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121148793
Principal investigator 1 Alnylam Pharmaceuticals Inc. $31.00 10/14/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149463
Principal investigator 1 Alnylam Pharmaceuticals Inc. $31.00 10/14/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149467
Principal investigator 1 Alnylam Pharmaceuticals Inc. $31.00 10/13/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149465
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149417
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149419
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149421
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149423
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149425
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149427
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149429
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/30/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149431
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/30/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149415
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/30/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149433
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/30/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149435
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/30/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149437
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/30/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149441
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/30/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149443
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/30/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149445
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149447
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149439
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149449
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149451
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149453
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149455
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149457
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149459
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149461
Principal investigator 1 Alnylam Pharmaceuticals Inc. $63,068.87 07/17/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121149257
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,643.00 07/01/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149259
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,643.00 07/01/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149261
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,643.00 07/01/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149263
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,643.00 07/01/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149265
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,643.00 07/01/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149267
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,643.00 07/01/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149365
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,643.00 07/01/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149367
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,643.00 07/01/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149369
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,643.00 07/01/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149371
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,643.00 07/01/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149373
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,643.00 07/01/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149375
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,039.00 07/01/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149377
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,643.00 07/01/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149379
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,643.00 07/01/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149381
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,039.00 07/01/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149383
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,643.00 07/01/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149385
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,643.00 07/01/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149387
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,039.00 07/01/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149389
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,643.00 07/01/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149391
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,643.00 07/01/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149393
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,643.00 07/01/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149395
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,602.80 07/01/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149397
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,643.00 07/01/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149399
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,643.00 07/01/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149401
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,643.00 07/01/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149403
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,643.00 07/01/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149405
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,643.00 07/01/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149407
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,643.00 07/01/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149409
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,643.00 07/01/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149411
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,643.00 07/01/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149413
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149203
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149205
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149207
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149209
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149211
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149213
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149215
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149217
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149219
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149221
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149223
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149225
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149227
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149229
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149231
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149233
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,200.00 05/24/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121149195
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,000.00 05/24/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121149197
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,825.00 05/24/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121149199
Principal investigator 1 Alnylam Pharmaceuticals Inc. $8,250.00 05/24/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121149201
Principal investigator 1 Amgen Inc. $194,125.00 05/24/2024 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH
OUTPOST Clinical Home Use Study No dispute reported 06/30/2026 1096311891
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149235
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149237
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149239
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149241
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149243
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149245
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149247
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149249
Principal investigator 1 Amgen Inc. $103,130.00 04/20/2024 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH
ASCEND P3 AD Extension No dispute reported 06/30/2026 1096309023
Principal investigator 1 Amgen Inc. $55,744.00 04/20/2024 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH
VOYAGER P3 AD Vaccine Study No dispute reported 06/30/2026 1096316352
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149129
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149131
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149141
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149143
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149145
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149147
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149149
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149151
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 03/04/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149161
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 03/04/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149163
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 03/04/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149165
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 03/04/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149167
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 03/04/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149169
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 03/04/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149171
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 03/04/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149173
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 03/04/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149175
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 03/04/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149177
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 03/04/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149179
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 03/04/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149181
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,169.00 03/04/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149183
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149133
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149135
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149153
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149155
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149157
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149159
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149191
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149193
Principal investigator 1 Amgen Inc. $22,872.48 02/26/2024 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH
OUTPOST Clinical Home Use Study No dispute reported 06/30/2026 1096311893
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149117
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149119
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149121
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149123
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149125
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149127
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149137
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Anchor Medical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121149139
Principal investigator 1 Amgen Inc. $21,255.48 01/26/2024 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH
ASCEND P3 AD Extension No dispute reported 06/30/2026 1096309025
Principal investigator 1 Amgen Inc. $11,033.05 01/02/2024 Non-covered Recipient Entity
ANCHOR MEDICAL RESEARCH
VOYAGER P3 AD Vaccine Study No dispute reported 06/30/2026 1096316354